Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists
Umapathysivam, M.; Araldi, E.; Hastoy, B.; Dawed, A. Y.; Vatandaslar, H.; Sengupta, S.; Kaufmann, A.; Thomsen, S. K.; Hartmann, B.; Jonsson, A. E.; Kabakci, H.; Thaman, S.; Grarup, N.; Have, C. T.; Faerch, K.; Gjesing, A. P.; Nawaz, S.; Cheeseman, J.; Neville, M. J.; Pedersen, O.; Walker, M.; Jennison, C.; Hattersley, A.; Hansen, T.; Karpe, F.; Holst, J. J.; Jones, A. G.; Ristow, M.; Mccarthy, M.; Pearson, E. R.; Stoffel, M.; Gloyn, A. L.
Show abstract
Patients with type 2 diabetes vary in their response to currently available therapeutic agents (including GLP-1 receptor agonists) leading to suboptimal glycemic control and increased risk of complications. We show that human carriers of hypomorphic T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase (PAM), as well as Pam-knockout mice, display increased resistance to GLP-1 in vivo. Pam inactivation in mice leads to reduced gastric GLP-1R expression and faster gastric emptying: this persists during GLP-1R agonist treatment and is rescued when GLP-1R activity is antagonized, indicating resistance to GLP-1s gastric slowing properties. Meta-analysis of human data from studies examining GLP-1R agonist response (including RCTs) reveals a relative loss of 44% and 20% of glucose lowering (measured by glycated hemoglobin) in individuals with hypomorphic PAM alleles p.S539W and p.D536G treated with GLP-1R agonist. Genetic variation in PAM has effects on incretin signaling that alters response to medication used commonly for treatment of T2D. (Funded by the Wellcome, Medical Research Council, European Union, NIHR Oxford Biomedical Research Centre, United Kingdom, Registered on ClinicalTrials.gov, NCT02723110.) Summary ParagraphType 2 diabetes (T2D) is a leading cause of morbidity and mortality globally1. Current management of T2D patients focuses on lowering glycemic exposure and reducing complications with lifestyle and pharmacological interventions2. Despite the availability of multiple medications to lower glycated hemoglobin (HbA1c), only 53% of individuals with T2D reach the glycemic target (HbA1c <7%)3, 4. There is potential to improve medication selection through "precision medicine" where patient specific factors (e.g. genetic markers) are used to indicate whether a patient is more or less likely to respond to a medication. Here we show that human carriers of hypomorphic T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase (PAM), as well as Pam-knockout mice, have reduced PAM enzyme activity, display increased resistance to glucagon like peptide 1 (GLP-1) in vivo and have reduced response to the GLP-1 receptor agonist. Meta-analysis of human data from studies examining GLP-1 receptor agonist response (including RCTs) reveals a relative loss of 44% and 20% of glucose lowering (measured by glycated hemoglobin) in individuals with hypomorphic PAM alleles p.S539W and p.D536G treated with GLP-1 receptor agonist. Genetic variation in PAM has effects on incretin signaling that alters response to medication used commonly for treatment of T2D.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- β-cell SENP1 facilitates responsiveness to incretins and limits oral glucose intolerance in high fat fed mice 96%
- Gut-derived GLP-1 released by rare sugar D-allulose cooperates with insulin to activate left-sided vagal afferents and enhance insulin sensitivity 94%
- Integrative proteogenomic analyses provide novel interpretations of type 1 diabetes risk loci through circulating proteins 94%
Similar papers in this journal
- Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant. 95%
- Chemical induction of gut β-like-cells by combined FoxO1/Notch inhibition as a glucose-lowering treatment for diabetes 95%
- Single-agent Foxo1 inhibition normalizes glycemia and induces gut β-like cells in streptozotocin-diabetic mice 94%
Similar papers in this journal
- Poor in-utero growth, reduced beta cell secretion and high plasma glucose in childhood are harbingers of glucose intolerance in young Indians 94%
- Early metabolic features of genetic liability to type 2 diabetes: cohort study with repeated metabolomics across early life 93%
- Specific type 1 diabetes risk genes underpin age-at-diagnosis and indicate joint defects in immunity, beta-cell fragility and responses to viral infections in early-onset disease. 92%
Similar papers in this journal
- The power of TOPMed imputation for the discovery of Latino enriched rare variants associated with type 2 diabetes 94%
- Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: an overview of the data from the epidemiological studies within the IMI DIRECT Consortium 93%
- Epigenome-wide association study of incident type 2 diabetes in Black and White participants from the Atherosclerosis Risk in Communities Study 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.